Clovis Oncology (DB:C6O) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

C6O Panoramica delle azioni

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Maggiori dettagli

C6O analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 5.6% all'anno negli ultimi 5 anni

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Patrimonio netto negativo

Non ha una capitalizzazione di mercato significativa ( €2M )

Gli ultimi report finanziari sono vecchi di più di 6 mesi

Clovis Oncology, Inc. Concorrenti

Epigenomics

XTRA:ECX

€616.0k

Paion

XTRA:PA8

€2.6m

co.don

XTRA:CNW

€6.5m

Sangui Biotech International

HMSE:SBH

€419.8k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Clovis Oncology
Prezzi storici delle azioni
Prezzo attuale dell'azione	€0.023
Massimo di 52 settimane	€2.46
Minimo di 52 settimane	€0.01
Beta	0.66
1Variazione di 1 mese	130.00%
Variazione a 3 mesi	-16.06%
Variazione di 1 anno	-99.07%
3Variazione a 3 anni	-99.60%
Variazione a 5 anni	-99.94%
Variazione dall'IPO	-99.86%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	C6O	DE Biotechs	DE Mercato
7D	53.3%	0.8%	0.8%
1Y	-99.1%	-18.3%	8.6%

Ritorno vs Industria: C6O ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -18.3 % nell'ultimo anno.

Rendimento vs Mercato: C6O ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.6 % nell'ultimo anno.

Volatilità dei prezzi

Is C6O's price volatile compared to industry and market?
C6O volatility
C6O Average Weekly Movement	104.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di C6O è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di C6O è aumentata da 91% a 105% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	413	Patrick Mahaffy	www.clovisoncology.com

Clovis Oncology, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Clovis Oncology con la sua capitalizzazione di mercato?
C6O statistiche fondamentali
Capitalizzazione di mercato	€2.18m
Guadagni(TTM)	-€226.19m
Ricavi(TTM)	€119.44m

0.0x

Rapporto P/S

0.0x

Rapporto P/E

C6O è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
C6O Conto economico (TTM)
Ricavi	US$133.02m
Costo del fatturato	US$31.59m
Profitto lordo	US$101.43m
Altre spese	US$353.33m
Guadagni	-US$251.91m

Ultimi guadagni dichiarati

Sep 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.73
Margine lordo	76.25%
Margine di profitto netto	-189.37%
Rapporto debito/patrimonio netto	-158.0%

Come si è comportato C6O nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

C6O Panoramica delle azioni

Premi

Analisi del rischio

Clovis Oncology, Inc. Concorrenti

XTRA:ECX

€616.0k

XTRA:PA8

€2.6m

XTRA:CNW

€6.5m

HMSE:SBH

€419.8k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue beats expectations

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €7.51

New 90-day high: €4.99

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.84

Clovis Oncology, Inc. to Report Q1, 2020 Results on May 05, 2020

Clovis Oncology, Inc. Presents Highlight Breadth and Potential of Clovis Oncology Products and Pipeline At ESMO Virtual Congress 2020

First half earnings released

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Clovis Oncology, Inc. Riepilogo dei fondamenti

0.0x

0.0x

Guadagni e ricavi